EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Akeso's enterprise value is HK$40,542 Mil.
Akeso's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was HK$2,376 Mil. Therefore, Akeso's EV-to-EBITDA for today is 17.06.
The historical rank and industry rank for Akeso's EV-to-EBITDA or its related term are showing as below:
HKSE:09926'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -135.19 Med: -24.68 Max: 17.36
Current: 17.08
During the past 6 years, the highest EV-to-EBITDA of Akeso was 17.36. The lowest was -135.19. And the median was -24.68.
HKSE:09926's EV-to-EBITDA is ranked worse than 62.86% of 455
companies
in the Biotechnology industry
Industry Median: 10.21
vs HKSE:09926: 17.08
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
As of today (2024-05-15), Akeso's stock price is HK$49.20.
Akeso's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was HK$2.647. Therefore, Akeso's PE Ratio for today is 18.59.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.
Akeso EV-to-EBITDA Historical Data
The historical data trend for Akeso's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Akeso's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Akeso's EV-to-EBITDA Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Akeso's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Akeso's EV-to-EBITDA falls into.
Akeso's current Enterprise Value is HK$40,542 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Akeso's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was HK$2,376 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Akeso (HKSE:09926) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Akeso's share price for today is HK$49.20.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Akeso's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was HK$2.647.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.
Thank you for viewing the detailed overview of Akeso's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
Akeso Inc is an investment holding company. The Company's subsidiaries were involved in research and development, production and commercialization of biopharmaceutical products. The company currently has a pipeline of over 30 drugs for the treatment of diseases like cancers, autoimmune diseases, inflammation and metabolic diseases, 17 of which have entered the clinical stage, including two first-in-class bi-specific antibody drugs (PD-1/CTLA-4 and PD-1/VEGF). The majority of the company's revenue is earned in Mainland China.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
HKSE:09926 has been successfully added to your 